<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509584</url>
  </required_header>
  <id_info>
    <org_study_id>2017-21</org_study_id>
    <secondary_id>2017-001198-18</secondary_id>
    <nct_id>NCT03509584</nct_id>
  </id_info>
  <brief_title>Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients</brief_title>
  <official_title>Phase I Multicenter Trial Combining Nivolumab, Alone or With Ipilimumab, Plus Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nivolumab is superior to docetaxel monotherapy as second line treatment in advanced stage&#xD;
      non-small cell lung cancer (NSCLC) patients. However, the long term survival advantage seems&#xD;
      to be limited to a 20% proportion of treated patients. To date, no definitive biomarker,&#xD;
      including tumor cells or infiltrative cells PD-L1 expression, has been demonstrated to&#xD;
      predict nivolumab (or other PD1 or PD-L1 inhibitors) efficacy. Ipilimumab has also suggested&#xD;
      efficacy in the same patient population. Finally, the addition of ipilimumab to nivolumab has&#xD;
      a suggested better efficacy over nivolumab alone in advanced stage NSCLC patients with an&#xD;
      acceptable safety profile.&#xD;
&#xD;
      In parallel, hypo-fractionated radiotherapy alone has been suggested to elicit the immune&#xD;
      system activity as demonstrated by the occurrence of an abscopal effect. Some case reports in&#xD;
      melanoma but also lung cancer patients reinforced this hypothesis.&#xD;
&#xD;
      Furthermore, preclinical and clinical data suggest that radiation may have a synergistic&#xD;
      effect with antibodies targeting the immune checkpoints (PD1, PD-L1, CTLA4) and improve&#xD;
      antitumor efficacy. Moreover, it has been shown that fractionated radiotherapy delivered in&#xD;
      combination with aPD-1 or aPD-L1 mAbs is able to generate efficacious CD8þ T-cell responses&#xD;
      that will in turn improve local tumor control, long-term survival, and protection against&#xD;
      tumor rechallenge.&#xD;
&#xD;
      Therefore, the combination of single fraction or hypo-fractionated radiotherapy with the anti&#xD;
      PD1 nivolumab and/or the anti CTLA4 ipilimumab warrants further investigation. However, a&#xD;
      large number of doses, sequences and schedules remain possible. In order to select the best&#xD;
      combination, a mathematical modeling of immunotherapy in cancer and its synergy with&#xD;
      radiotherapy has been set up. This work provides with mathematical formulas to link the drug&#xD;
      serum concentrations of nivolumab and ipilimumab, and the dose of radiation therapy, to the&#xD;
      immune response. In silico, the single and three fractions schedule have been found to have&#xD;
      the same efficacy while activation of the immune response seems to be better using a&#xD;
      hypo-fractionated (less than 6 fractions) radiotherapy in vivo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of immune related adverse events</measure>
    <time_frame>48 weeks</time_frame>
    <description>evaluate the safety of the combination of the radiotherapy plus nivolumab alone or in combination with ipilimumab, by physical examinations</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>part #1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-small cell lung cancer (NSCLC) patients with bone metatase(s) eligible for localized hypo-fractionated radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>part #1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-small cell lung cancer (NSCLC) patients with bone metatase(s) eligible for localized hypo-fractionated radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>part #2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NSCLC patients eligible for a localized radiotherapy of one target lesion (outside the brain)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>part #2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NSCLC patients eligible for a localized radiotherapy of one target lesion (outside the brain)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated radiotherapy</intervention_name>
    <description>Stereotactic hypo-fractionated irradiation (3 x 8 Gys) radiotherapy fraction</description>
    <arm_group_label>part #1a</arm_group_label>
    <arm_group_label>part #1b</arm_group_label>
    <arm_group_label>part #2a</arm_group_label>
    <arm_group_label>part #2b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>administration of nivolumab</description>
    <arm_group_label>part #1a</arm_group_label>
    <arm_group_label>part #1b</arm_group_label>
    <arm_group_label>part #2a</arm_group_label>
    <arm_group_label>part #2b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>administration of ipilimumab</description>
    <arm_group_label>part #1b</arm_group_label>
    <arm_group_label>part #2b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced NSCLC&#xD;
&#xD;
          -  One site of measureable disease by RECIST 1.1&#xD;
&#xD;
          -  Eligible for localized palliative radiotherapy of a bone lesion as per current&#xD;
             national and international recommendations (part #1) or&#xD;
&#xD;
          -  Ability to tolerate hypo-fractionated radiotherapy of a tumoral lesion chosen&#xD;
             according to the lower risk of radiation adverse event (lymph node &gt; subcutaneous &gt;&#xD;
             liver &gt; bone &gt; lung) (part #2)&#xD;
&#xD;
          -  Received at least one prior line of therapy for incurable or metastatic NSCLC&#xD;
&#xD;
          -  Disease progression at study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received systemic anticancer therapy within the previous 21 days&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled&#xD;
             infections or concurrent illness, unrelated to the tumor, requiring active therapy&#xD;
&#xD;
          -  Any condition requiring concurrent systemic immunosuppressive therapy&#xD;
&#xD;
          -  Known immunodeficiency disorders, either primary or acquired&#xD;
&#xD;
          -  Bone lesion with indication of surgery (part #1) ; especially in case of spinal&#xD;
             compression.&#xD;
&#xD;
          -  Known leptomeningeal disease&#xD;
&#xD;
          -  Active malignancies within 12 months with the exception of those with a negligible&#xD;
             risk of metastasis or death treated with expected curative outcome&#xD;
&#xD;
          -  Prior treatment with immune checkpoints inhibitors&#xD;
&#xD;
          -  Administration of a live, attenuated vaccine within 30 days prior to first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Long-term use of systemic corticosteroids (unless to a dose of 20mg of&#xD;
             methylprednisolone)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urielle Desalbres</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice Barlesi</last_name>
    <email>fabrice.barlesi@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabrice Barlesi</last_name>
      <email>fabrice.barlesi@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 10, 2018</study_first_submitted>
  <study_first_submitted_qc>April 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

